Please login to the form below

Not currently logged in


This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Biogen now has two mid-stage trials with anti-amyloid drugs which appear to be positive in Alzheimer’s, with its aducanumab candidate also showing a statistically-significant improvements in cognition ... The biotech was forced to enlarge the size of

Latest news

More from news
Approximately 5 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Biogen has begun enrolment in two phase III trials of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....